Ocular Therapeutix, Inc (OCUL) Stock Price & Analysis
Ocular Therapeutix, Inc (OCUL) fell 1.33% to USD 8.51 as of July 25, 2026 at 05:27 UTC, according to Nexqual real-time market data.
OCUL last closed at USD 8.62; the session ranged USD 8.43–8.71 on volume of 1,126,615 shares. Market capitalization is $1.86B, with a 52-week range of USD 6.23–16.44 (NGM). Source: Nexqual, July 25, 2026 at 05:27 UTC.
Key Statistics (as of July 25, 2026 at 05:27 UTC)
| Price | USD 8.51 |
|---|---|
| Change | ▼ 1.33% (down) |
| Previous Close | USD 8.62 |
| Open | USD 8.66 |
| Day Range | USD 8.43 – 8.71 |
| 52-Week Range | USD 6.23 – 16.44 |
| Volume | 1,126,615 shares |
| Market Cap | $1.86B |
| Exchange | NGM |
Technical Analysis (OCUL)
Nexqual's technical model rates OCUL "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 05:27 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 40.83 (neutral) |
| vs SMA50 | Below (USD 9.14) |
| MACD | -0.19 (negative) |
Analyst Ratings (OCUL)
Wall Street analysts rate OCUL "Strong Buy" based on 11 analysts, with a mean price target of USD 27.09 (range USD 18–34), per Nexqual as of July 25, 2026 at 05:27 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 27.09 |
| High Target | USD 34 |
| Low Target | USD 18 |
| Buy / Hold / Sell | 11 / 0 / 0 |
Earnings (OCUL)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -0.39 |
| Revenue Estimate | $13.20M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.4 vs est -0.32 ▼ miss |
| 2025-12-31 | USD -0.29 vs est -0.34 ▲ beat |
| 2025-09-30 | USD -0.38 vs est -0.35 ▼ miss |
| 2025-06-30 | USD -0.39 vs est -0.36 ▼ miss |
Source: Nexqual, July 25, 2026 at 05:27 UTC.
Financials & Fundamentals (OCUL)
| Total Revenue | $52.04M |
|---|---|
| Revenue Growth (YoY) | +0.80% |
| Gross Margin | +0.00% |
| Operating Margin | -865.46% |
| Profit Margin | +0.00% |
| ROE | -68.55% |
| Debt / Equity | 13.66 |
| Current Ratio | 14.81 |
| Total Cash | $666.70M |
| Total Debt | $79.46M |
| Free Cash Flow | $-148.76M |
Source: Nexqual, July 25, 2026 at 05:27 UTC.
Financial Health Score (OCUL)
Nexqual rates Ocular Therapeutix, Inc's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 05:27 UTC.
| Growth | Critical — Revenue -18% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $667M cash vs $79M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$149M, burning cash |
| Efficiency | Critical — ROE -69%, ROA -32.9% |
Ownership (OCUL)
| Insider Ownership | +0.94% |
|---|---|
| Institutional Ownership | +95.81% |
| Shares Outstanding | 218.96M |
| Float | 184.37M |
| Short % of Float | +14.40% |
Source: Nexqual, July 25, 2026 at 05:27 UTC.
Leadership (OCUL)
Ocular Therapeutix, Inc is led by Pravin U. Dugel (age 61), Executive Chairman, President & CEO, per Nexqual as of July 25, 2026 at 05:27 UTC.
| Executive Chairman, President & CEO | Pravin U. Dugel (age 61) |
|---|---|
| Chief Operating Officer (Leave of Absence) | Donald Notman |
| Chief Strategy Officer | Sanjay Nayak MBBS (age 55) |
| CFO & Principal Accounting Officer | Jason Robins (age 48) |
| Chief Scientific Officer | Jeffrey S. Heier (age 64) |
Major Backers & Investors (OCUL)
Notable institutional backers of Ocular Therapeutix, Inc include FMR, LLC, Deep Track Capital, Lp, Fidelity, according to Nexqual as of July 25, 2026 at 05:27 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.91% |
| Deep Track Capital, Lp | 8.99% |
| Fidelity | 7.71% |
| Avoro Capital Advisors LLC | 5.62% |
| Summer Road LLC | 5.43% |
| Venrock Adviser, LLC | 4.73% |
| Price (T.Rowe) Associates Inc | 2.69% |
| Point72 Asset Management, L.P. | 2.53% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.12% |
| Vanguard Group | 7.86% |
Source: Nexqual, July 25, 2026 at 05:27 UTC.
From Ocular Therapeutix, Inc's Latest SEC 10-K Filing (filed 2026-02-05)
Key Strengths & Strategy (as disclosed to the SEC)
- Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States.
- The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
- It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension.
- The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KPTI | Karyopharm Therapeutics Inc. | USD 7.41 | ▲ 3.2% |
| OMER | Omeros Corporation | USD 9.79 | ▼ 0.51% |
| EYPT | EyePoint, Inc. | USD 12.19 | ▼ 3.71% |
| ALDX | Aldeyra Therapeutics, Inc. | USD 1.52 | ▼ 10.59% |
| PTCT | PTC Therapeutics, Inc. | USD 76.82 | ▼ 2.02% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 05:27 UTC. This page is informational and not investment advice.